Setting the record straight: activity of gemcitabine monotherapy for breast cancer.
Reichardt
Peter
P
Miles
David
D
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced; D010166:Palliative Care / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D000093542:Gemcitabine
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine